质子泵抑制剂的新成员——埃索美拉唑

被引:55
作者
姚光弼
机构
[1] 上海静安区中心医院临床免疫研究中心
关键词
埃索美拉唑; 愈合率; 食管炎; 异构体; 食道炎; 食管疾病; 质子泵抑制剂; 奥美拉唑;
D O I
暂无
中图分类号
R975 [消化系统药物];
学科分类号
摘要
引用
收藏
页码:37 / 39
页数:3
相关论文
共 10 条
[1]  
E fficacy and safety of esomeprazole compared w ith omeprazole in GERD patientsw ith erosive esophagitis: a random ized controlled trial. R ichter J E,Kahrilas P J,Johanson J,et al. The American journal of Gastroenterology . 2001
[2]  
Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Kahrilas PJ,Falk GW,Johnson DA,et al. Alimentary Pharmacology and Therapeutics . 2000
[3]  
Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitor[poster]. Rohss K,Wilder-Smith CH,Clarr-Nilsson C,et al. Gastroenterology . 2001
[4]  
Esomeprazole provides improved acid control vs.omeprazole in patients with symptoms of gastro-oesophaged reflux disease. Lind T,Rydberg L,Kyleback A,et al. Alimentary Pharmacology and Therapeutics . 2000
[5]  
Esomeprazole-based helicobacter pylori eradication therapy and the effect of antibiotic resistance:results of three US multicenter, double-blind trials. Laine L,Fennerty MB,Osato M,et al. The American journal of Gastroenterology . 2000
[6]  
Pharmacokinetics (PK) and dose-response relationship of esomeprazole[Abstract]. Andersson T,Rohss K,Hassan-Alin M,et al. Gastroenterology . 2000
[7]  
Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Hassan-Alin M,Andersson T,Bredberg E,et al. European Journal of Clinical Pharmacology . 2000
[8]  
GUT[P]. YAMAMOTO HIROSHI;WATANABE HIROSHI;IMAI YUICHI;ISHIKAWA SHIRO;TSUBOKO HISASHI;KATO KENJI.日本专利:JP2000346293A,2000-12-15
[9]  
A critical analysis of the new PPI esomeprazole. Castell DO,Fennerty MB,Johnson DA,et al. AGA New Dew Drug Review . 2001
[10]  
Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized double-blind, placebo-controlled study of efficacy and safety. Johnson DA,Benjamin SB,Vakil NB,et al. The American journal of Gastroenterology . 2001